San Francisco Mammography Registry

The research team focuses on the epidemiology of invasive breast cancer and ductal carcinoma in situ, factors that influence the accuracy of screening mammography, improving breast cancer risk assessment and breast cancer detection, epidemiologic, biologic and genetic studies of breast density, and predictors of breast cancer recurrence. We use well characterized study populations to address our research questions.

The San Francisco Mammography Registry (SFMR) is an ethnically and economically diverse population-based breast imaging registry. Its overall goal is to collect demographic, clinical, and risk factor information, as well as breast imaging interpretations, cancer outcomes obtained through linkage with population-based California Cancer Registry, and vital status through linkage with the California Department of Health Services Vital Records. The SFMR began prospective data collection on women undergoing mammography in San Francisco County in 1995 and expanded data collection to Marin County mammography facilities in 2003, San Mateo and Sonoma counties in 2011, and Alameda and Contra Costa county in 2012. Since the registry’s inception, information on over 3,000,000 breast imaging examinations and 49,000 breast cancers from 645,000 women has been collected from 20 radiology facilities. Annually, information is collected on about 200,000 breast imaging examinations and 2,500 cancers. To learn more about the SFMR visit; (

The SFMR participates in the NCI-funded Breast Cancer Surveillance Consortium (BCSC), which consists of six breast imaging registries across the U.S. ( Dr. Kerlikowske is co-PI of the BCSC which has published over 600 scientific publications and created a breast cancer risk calculator used in clinical practice. To learn more about the BCSC visit; (

Bioregistry to Identify Women at High Breast Cancer Risk

We are evaluating innovative methods to measure breast density and parenchymal texture features prospectively on routine digital screening examinations for the purpose of providing more accurate and precise measures of breast cancer risk and screening outcomes. We have established a large and ethnically diverse cohort of women within the SFMR who undergo mammography to prospectively test and develop density methods.

Predictors of Subsequent Tumors Among with DCIS

We established a cohort of 1,741 women with ductal carcinoma in situ (DCIS) diagnosed and treated with lumpectomy alone in the greater San Francisco Bay Area.  We are examining molecular markers, histopathology markers, and clinical factors to estimate an individual’s risk for subsequent tumors. Our objective is to provide women diagnosed with DCIS individualized accurate risk estimates of subsequent invasive breast cancer to improve risk stratification and decision-making about surveillance and adjuvant therapy to reduce overtreatment of DCIS and associated side-effects.